Ark Invest analyst says these are two of the firm's favorite genomic revolution plays

In a CNBC interview, Ark Invest analyst Simon Barnett explains the firm's belief in Adaptive Biotechnologies and Invitae.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.